TabletsClinical Overview
Tofacitinib Tablets (5mg, 10mg immediate-release, 11mg, 22mg Extended Release) is a first-in-class oral Janus Kinase (JAK-1 and JAK-3 preferential) inhibitor on the WHO Model List framework. It blocks the intracellular catalytic domain of JAK kinases, halting STAT transcription factor phosphorylation and shutting down signaling for key inflammatory cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, and interferon-gamma). Indicated for moderate-to-severe active Rheumatoid Arthritis (RA) with inadequate response or intolerance to methotrexate, active Psoriatic Arthritis, Ankylosing Spondylitis, and moderate-to-severe Ulcerative Colitis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Immediate-release: Take orally 5 mg twice daily with water, with or without food. Extended-release: Take 11 mg once daily swallowed whole; do NOT crush, split, or chew. Screen for latent tuberculosis (TB) and hepatitis B/C prior to initiation. Co-administration with biologic DMARDs is NOT recommended.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Upper respiratory tract infections, headache, diarrhea, nasopharyngitis, hypertension, elevated lipid levels (cholesterol, HDL, LDL), elevated transaminases. Rare/Severe: Serious opportunistic infections (TB, fungal, viral shingles reactivation), major adverse cardiovascular events (MACE: MI, stroke), deep vein thrombosis / pulmonary embolism, malignancies (lymphoma, lung cancer), and gastrointestinal perforation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Serious infections (tuberculosis, invasive fungal infections); test for latent TB prior to starting. Black Box Warning: Increased all-cause mortality and Major Adverse Cardiovascular Events (MACE: MI, stroke) in patients >=50 years with CV risk factors. Black Box Warning: Thrombosis (DVT, PE, arterial thrombosis). Black Box Warning: Malignancy (lymphomas, lung cancer). Reduce dose in moderate-to-severe renal or hepatic impairment.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or analgesic treatment guidance. Always consult a registered physician or orthopedic specialist before taking pain relievers, anti-inflammatory medications, or anti-arthritic therapies.
Tofacitinib 2.0% Ointment
Tofacitinib (2% w/w ointment) is a topical Janus kinase (JAK1/JAK3) inhibitor. It blocks intracellular JAK-STAT signaling pathways for multiple key inflammatory cytokines (IL-4, IL-13, IL-22, IL-31), rapidly reducing itch and clearing epidermal inflammation in inflammatory skin diseases without causing steroid-induced skin atrophy. Indicated for atopic dermatitis, alopecia areata, and plaque psoriasis.
Tofacitinib Extended Release Tablets 11mg
Tofacitinib Tablets (5mg, 10mg immediate-release, 11mg, 22mg Extended Release) is a first-in-class oral Janus Kinase (JAK-1 and JAK-3 preferential) inhibitor on the WHO Model List framework. It blocks the intracellular catalytic domain of JAK kinases, halting STAT transcription factor phosphorylation and shutting down signaling for key inflammatory cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, and interferon-gamma). Indicated for moderate-to-severe active Rheumatoid Arthritis (RA) with inadequate response or intolerance to methotrexate, active Psoriatic Arthritis, Ankylosing Spondylitis, and moderate-to-severe Ulcerative Colitis.
Tofacitinib Extended Release Tablets 22mg
Tofacitinib Tablets (5mg, 10mg immediate-release, 11mg, 22mg Extended Release) is a first-in-class oral Janus Kinase (JAK-1 and JAK-3 preferential) inhibitor on the WHO Model List framework. It blocks the intracellular catalytic domain of JAK kinases, halting STAT transcription factor phosphorylation and shutting down signaling for key inflammatory cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, and interferon-gamma). Indicated for moderate-to-severe active Rheumatoid Arthritis (RA) with inadequate response or intolerance to methotrexate, active Psoriatic Arthritis, Ankylosing Spondylitis, and moderate-to-severe Ulcerative Colitis.
Tofacitinib Tablets 5mg
Tofacitinib Tablets (5mg, 10mg immediate-release, 11mg, 22mg Extended Release) is a first-in-class oral Janus Kinase (JAK-1 and JAK-3 preferential) inhibitor on the WHO Model List framework. It blocks the intracellular catalytic domain of JAK kinases, halting STAT transcription factor phosphorylation and shutting down signaling for key inflammatory cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, and interferon-gamma). Indicated for moderate-to-severe active Rheumatoid Arthritis (RA) with inadequate response or intolerance to methotrexate, active Psoriatic Arthritis, Ankylosing Spondylitis, and moderate-to-severe Ulcerative Colitis.